PLYMOUTH, Minn., Feb. 27 /PRNewswire-FirstCall/ -- ev3 Inc. today announced the appointment of Daniel J. Levangie to its Board of Directors and Audit Committee as an independent director effective as of February 23, 2007. Mr. Levangie is the President, Surgical Products Division, and an Executive Vice President and member of the Board of Directors of Cytyc Corporation, a leading provider of surgical and diagnostic products targeting women's health and cancer diagnostics.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO )
In addition to his current positions, Mr. Levangie has held several positions with Cytyc Corporation, including Executive Vice President and Chief Operating Officer from 2000 to 2006 and Vice President of Commercial Operations from 1997 to 2000. He also served as Chief Executive Officer and President of Cytyc Health Corporation from July 2002 to December 2003. Mr. Levangie has been with Cytyc Corporation since 1992. Mr. Levangie is a member of the Board of Directors of Dune Medical Devices Ltd., a privately owned medical device company engaged in the development and commercialization of devices for real time tissue characterization.
The appointment of Mr. Levangie to ev3's Audit Committee brings ev3 back into compliance with Nasdaq Rule 4350, which stipulates that every Nasdaq-listed company must have an audit committee with at least three members, all of whom must be independent under Nasdaq Rule 4200 and applicable Securities and Exchange Commission rules.
About ev3 Inc.
ev3 is a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. For more information, please visit http://www.ev3.net .
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited to, in no particular order: product demand and market acceptance, the impact of competitive products and pricing, and success of clinical testing. More detailed information on these and additional factors which could affect ev3 Inc.'s operating and financial results are described in the company's filings with the Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q and annual report on Form 10-K. ev3 Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, ev3 Inc. undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comev3 Inc.CONTACT: INVESTOR RELATIONS CONTACTS, Patrick Spangler, CFO of ev3 Inc.,+1-763-398-7000, pspangler@ev3.net ; or Marian Briggs, +1-612-455-1742,mbriggs@psbpr.com , or Nancy Johnson, +1-612-455-1745, njohnson@psbpr.com ,both of Padilla Speer Beardsley
Web site: http://www.ev3.net/
